Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial.
Lancet HIV
; 10(8): e497-e505, 2023 08.
Article
in En
| MEDLINE
| ID: mdl-37451297
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
HIV Infections
/
HIV-1
/
Anti-HIV Agents
Type of study:
Clinical_trials
Limits:
Adult
/
Humans
Language:
En
Journal:
Lancet HIV
Year:
2023
Document type:
Article
Country of publication: